I agree with you regarding CYDY being the better i
Post# of 148158
RLFTF will announce there results soon, and HGEN looks to be a month or more behind.
Based on the knowledge and science provided by others,I believe that our MOA is superior. The trial results will show if this is true.
My point is that competition isn't our biggest challenge currently. We need revenue. If COVID provides us a small amount of revenue (comparatively speaking) it will be enough IMO to stop dilution and fund all of the indications that we pursue.
Sure, if we sell more LL for COVID we will make more money, and we will see a higher share price. I'm all for that.
But my focus is on the longer term potential of Cytodyn. And COVID looks to be the catalyst for reaching that potential.